stockrow
Friday 6 November 2026
Export HSCS’s income statement to Excel — free account
HeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025.
- Revenue
- −46.2%
- EPS
- +45.6%
- Free cash flow
- +18.2%
Quarter to July 2026, against a year earlier
2.81
0.14
+5.24%
Follow HSCS
Alert me
HeartSciences Inc. (HSCS) P/E ratio
HeartSciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Oct 2025 | 0.0× | — |
| Jul 2025 | 0.0× | — |
| Jan 2024 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MODD Modular Medical, Inc. compare | n/m |
| PAVM PAVmed Inc. compare | n/m |
| PETV PetVivo Holdings, Inc. compare | n/m |
| CTSO Cytosorbents Corporation compare | n/m |
| HSCS HeartSciences Inc. | n/m |
| RBOT Vicarious Surgical Inc. compare | n/m |
| IRIX IRIDEX Corporation compare | n/m |
| ARAY Accuray Incorporated compare | n/m |
| ITOC iTonic Holdings Ltd. compare | — |
| Medical Devices industry median | 24.9× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)